NCT05039632View on ClinicalTrials.gov

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions

Advanced Malignant Solid NeoplasmMetastatic Malignant Neoplasm in the LiverMetastatic Malignant Neoplasm in the LungMetastatic Malignant Solid Neoplasm

Interventions

OTHER

Hafnium Oxide-containing Nanoparticles NBTXR3

Given intratumorally

RADIATION

Radiation Therapy

Undergo Abscopal radiation therapy

RADIATION

Radiation Therapy

Undergo RadScopal radiation therapy

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER